Treace Medical Concepts opened at $5.06, in line with its previous close of $5.06. In the last trading session, the stock traded between $4.45 and $5.07. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Treace Medical Concepts is now worth
$ 19.32
resulting in a loss of
$ 80.68 (80.68%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.61 (-11.96%)
Day High
$5.07
Day Low
$4.45
Day Open
$5.06
Prev Close
$5.06
Volume
1,27,350
1W Return
4.28%
1M Return
-3.47%
3M Return
10.44%
6M Return
150.28%
1Y Return
-31.98%
Market Cap ($ Mn)
290
PE Ratio
-
PB Ratio
4.47
PEG Ratio
-
ROE
-59.92%
ROCE
-33.81%
EPS (TTM)
$-0.25
1 Week
4.28%
1 Month
-3.47%
3 Months
10.44%
6 Months
150.28%
9 Months
93.70%
Halper Sadeh investigates Treace Medical for potential fiduciary duty breaches
Halper Sadeh LLC investigates Treace Medical Concepts for fiduciary duty breaches. Long-term shareholders may seek governance reforms and financial recovery. Firm offers contingent fee representation with no upfront legal costs.
1mo agoTreace Medical presents 5-year Lapiplasty data showing low recurrence
Treace Medical presents milestone 5-year ALIGN3D Lapiplasty data at AOFAS 2026. Radiographic recurrence rates were 0.8% (HVA>20%) and 5.3% (HVA>15%) at 5 years. Patients returned to weight bearing in an average of 8.4 days post-Lapiplasty. MTA3D Adductoplasty interim results show 7.6 days to weight bearing. SPRINT SpeedPlate study reports 96.6% union rate at 12 months.
1mo agoTreace Medical Q2 EPS beats, raises FY26 sales guidance to $204M-$212M
Treace Medical Concepts delivered a Q2 EPS beat of $(0.24) versus $(0.30) estimates, driven by cost discipline. The company raised FY26 revenue guidance to $204M-$212M, exceeding consensus, while maintaining strong liquidity and reducing cash burn.
2mo agoTruist Securities raises Treace Medical Concepts target to $4
Truist Securities analyst Richard Newitter maintains a Hold rating on Treace Medical Concepts (NASDAQ: TMCI) and raises the price target from $2 to $4, signaling a revised valuation outlook.
3mo agoJohnson Fistel investigates Treace Medical over alleged fiduciary breaches
Johnson Fistel, PLLP is investigating Treace Medical Concepts, Inc. for alleged breaches of fiduciary duty involving misleading statements about its Lapiplasty product and revenue decline. Shareholders holding shares since before May 8, 2023, may seek governance reforms and fund recovery at no cost. The firm represents investors in securities class actions and derivative lawsuits.
3mo agoTreace completes first surgical case with HyperPlate XM implant
Treace Medical Concepts announced the successful completion of the first surgical case using its HyperPlate XM Dynamic Compression Locking Implant, expanding its SpeedPlate platform into larger midfoot and hindfoot applications. The technology features FastPitch locking screws and an ultra-low profile design, supported by new single-use instruments. Full commercialization is expected in the third quarter of 2026.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $104.57 | +1.88% | $1,80,946.15M | 36.28 | |
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $42.69 | +0.61% | $61,867.63M | 18.96 | |
| $94.44 | +2.90% | $54,435.22M | 53.70 | |
| $198.34 | +1.63% | $54,025.24M | 44.07 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $71.13 | +1.86% | $34,384.24M | 54.55 | |
| $79.93 | +1.67% | $30,162.46M | 36.04 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 |
An investment of $100 made 5 years ago in Treace Medical Concepts is now worth
$ 19.32
resulting in a loss of
$ 80.68 (80.68%)
Note: Past profits do not guarantee future returns.
